10-K · April 29, 2026
Sangamo Therapeutics, Inc. reported troubling financial results for the year ended December 31, 2025, with significant declines in revenue and large operating losses. The company's performance indicates potential for…
Earnings analysis · 10-Q
SGMO earnings analysis
Filed May 14, 2026 · Our reading of the company's report
The latest report
Sangamo Therapeutics reported a significant decline in revenues for Q1 2026, generating only $1.44 million, a decrease of 77.6% year-over-year, and an EPS of -$0.11, missing expectations. The company faces critical…
Read full summary
Sangamo Therapeutics reported a significant decline in revenues for Q1 2026, generating only $1.44 million, a decrease of 77.6% year-over-year, and an EPS of -$0.11, missing expectations. The company faces critical liquidity challenges, with cash expected to last only until Q3 2026, and continues to explore various strategic options, including potential bankruptcy.
Reported figures
- Earnings per share
- $-0.11
What stood out
-
Massive Revenue Decline
Total revenue decreased by $4.99 million to $1.44 million, down 77.6% from $6.437 million YOY.
-
Consistent EPS Loss
EPS reported at -$0.11, down from -$0.08 in the previous year.
-
Operating Expenses Decrease
Total operating expenses declined by $2.7 million to $33.4 million, down 7% from the year prior.
-
Increased Cash Reserves
Cash and cash equivalents rose to $27.6 million from $20.9 million at year-end.
-
Sustained R&D Expenditure
R&D expenses rose slightly by $0.6 million to $26.6 million, mainly due to BLA readiness activities.
-
Active Stock Sale Program
$129.5 million remains available under the sales agreement as of March 31, 2026.
What to watch
-
Potential Bankruptcy
Management warns of a possible need to cease operations or liquidate assets if additional funding is not secured.
-
Delisted from Nasdaq
The company's stock was suspended from Nasdaq trading on May 5, 2026, following ongoing compliance failures.
-
Severe Cash Flow Concerns
With current cash reserves, liquidity is expected to last only until Q3 2026, posing a significant operational risk.
Management's outlook
Management anticipates substantial operational cuts unless significant capital is raised.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.